Non-melanoma Skin Cancer Market by Type and Geography - Forecast and Analysis 2022-2026

The non-melanoma skin cancer market share is expected to increase to USD 180.97 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.76%.

This non-melanoma skin cancer market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers non-melanoma skin cancer market segmentation by type (BCC and SCC) and geography (North America, Europe, Asia, and Rest of World (ROW)).

The non-melanoma skin cancer market report also offers information on several market vendors, including 3M Corp., Almirall SA, Amgen Inc., Bausch Health Companies Inc., Bristol Myers Squibb Co., Elekta AB, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, iCAD Inc., Merck and Co. Inc., Mylan N.V, Novartis AG, Pfizer Inc., Sensus Healthcare Inc., Sun Pharmaceutical Industries Ltd., Varian Medical Systems Inc., and Vidac Pharma among others.

What will the Non-melanoma Skin Cancer Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Non-melanoma Skin Cancer Market Size for the Forecast Period and Other Important Statistics

 

Non-melanoma Skin Cancer Market: Key Drivers, Trends, and Challenges

The NMSC coverage and support is notably driving the non-melanoma skin cancer market growth, although factors such as few drugs in the pipeline for NMSC may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the non-melanoma skin cancer industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Non-melanoma Skin Cancer Market Driver

One of the key factors driving growth in the non-melanoma skin cancer market is the NMSC coverage and support. Direct medical costs for the treatment of NMSC include diagnosis costs, treatment costs, repair charges, facility fees, pathology costs, and other peripheral costs. Treatment costs include destruction, excision, and Mohs surgery, which are covered by most payers and Medicare. Most pharmacotherapy approaches require substantial efforts and multiple physician visits compared with surgery. Thus, pharmacotherapy approaches are less preferred by physicians. Drugs are reimbursed based on evaluation and management codes. Documents regarding the type and severity of patient conditions and bills for reimbursement must be provided. The choice of treatment is probably based on the disease type, severity, and patient demand because of differences in reimbursement for the two approaches, namely surgery and drugs. Most drugs for NMSC are reimbursed by the manufacturing company in the form of coupons and patient assistance for low-income groups.

Key Non-melanoma Skin Cancer Market Trend

The increasing incidence of NMSC is a non-melanoma skin cancer market trend that is expected to have a positive impact on the industry in the coming years. Globally, NMSC is the most common malignancy associated with considerable morbidity and substantial cost, as well as comparatively small but significant mortality. According to US national claims and survey databases, there has been a significant increase in the number of NMSCs and affected individuals in the US. From 1992 to 2012, the incidence rate of skin cancer continued to rise, with a 100% increase among the Medicare fee-for-service population. From 2006 to 2019, there was a 35% increase in the NMSC incidence rate among the US population.

Key Non-melanoma Skin Cancer Market Challenge

The few drugs in the pipeline for NMSC will be a major challenge for the non-melanoma skin cancer market during the forecast period. The drug pipeline for NMSC has very few molecules because of the low amount of R&D in this area. Non-disease-modifying drugs are under evaluation. Most drugs are being evaluated for palliative care or as adjuvant therapy. The topical drugs used for NMSC are imiquimod (Aldara and ZYCLARA) and 5-fluorouracil (5-FU, Efudex, and Actikerall). Various studies are being conducted to test newer targeted drugs for the treatment of advanced SCC. Cells from this type of cancer consist of the epidermal growth factor receptor (EGFR). Drugs that target this protein, such Cetuximab (ERIBUTEX), are being tested in clinical trials. Erlotinib therapy is also being evaluated for NMSC. BCC rarely reaches an advanced stage. This type of cancer can be difficult to treat if it is not addressed at the early stages. The lack of a strong pipeline of NMSC drugs and the long approval time for drugs are expected to hamper the growth of the global NMSC market during the forecast period.

This non-melanoma skin cancer market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global non-melanoma skin cancer (NMSC) market as a part of the pharmaceutical market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the non-melanoma skin cancer market during the forecast period.

Who are the Major Non-melanoma Skin Cancer Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• 3M Corp.
• Almirall SA
• Amgen Inc.
• Bausch Health Companies Inc.
• Bristol Myers Squibb Co.
• Elekta AB
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• iCAD Inc.
• Merck and Co. Inc.
• Mylan N.V
• Novartis AG
• Pfizer Inc.
• Sensus Healthcare Inc.
• Sun Pharmaceutical Industries Ltd.
• Varian Medical Systems Inc.
• Vidac Pharma

 

This statistical study of the non-melanoma skin cancer market encompasses successful business strategies deployed by the key vendors. The non-melanoma skin cancer market is fragmented and the vendors are deploying growth strategies such as focusing on expanding their network and distributing their products in different countries, approaching dermatologists, and investing in the development of innovative products to compete in the market.

Product Insights and News

• 3m.com - The company offers non-melanoma skin cancer that includes aldara imiquimod cream to treat superficial basal cell carcinoma, a form of non-melanoma skin cancer.

• 3m.com - The safety and industrial segment focuses on industrial abrasives and finishing for metalworking applications, autobody repair solutions, closure systems for personal hygiene products, masking, and packaging materials.

To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The non-melanoma skin cancer market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Non-melanoma Skin Cancer Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the non-melanoma skin cancer market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Non-melanoma Skin Cancer Market?

For more insights on the market share of various regions Request for a FREE sample now!

36% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for non-melanoma skin cancer in North America. Market growth in this region will be slower than the growth of the market in other regions.

The strong prevalence of BCC will facilitate the non-melanoma skin cancer market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the outbreak of COVID-19 affected the economies of various countries in North America, especially the US. A rise in the number of COVID-19 cases in the first quarter of 2021 led to partial lockdowns in several countries, including Canada and Mexico. The COVID-19 pandemic had a significant short-term and long-term impact on the pharmaceutical sector, which needs identification and appropriate planning to reduce its socioeconomic burden. However, with the initiation of vaccination drives, the market is expected to grow during the forecast period.

What are the Revenue-generating Type Segments in the Non-melanoma Skin Cancer Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The non-melanoma skin cancer market share growth by the BCC segment will be significant during the forecast period. BCC accounts for approximately 80% of NMSC. The occurrence of BCC is estimated to have been rising by 2% a year in the US and 5% a year in Europe in the past few years. In APAC, Australia has the highest number of patients who have been diagnosed with BCC by the age of 70. In the last few years, there has been an increase in surgical treatments and an increase in awareness of BCC among the general population and physicians. Although the mortality rate for BCC is low, BCCs can lead to severe disfigurement of the body. Moreover, it has been observed that the occurrence of BCC is 11.4 times more common in HIV-infected individuals than in the general population. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the non-melanoma skin cancer market size and actionable market insights on the post-COVID-19 impact on each segment.

 

Non-melanoma Skin Cancer Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 5.76%
Market growth 2022-2026	$180.97 million
Market structure	Fragmented
YoY growth (%)	5.41
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 36%
Key consumer countries	US, Canada, UK, Germany, Japan, and China
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	3M Corp., Almirall SA, Amgen Inc., Bausch Health Companies Inc., Bristol Myers Squibb Co., Elekta AB, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, iCAD Inc., Merck and Co. Inc., Mylan N.V, Novartis AG, Pfizer Inc., Sensus Healthcare Inc., Sun Pharmaceutical Industries Ltd., Varian Medical Systems Inc., and Vidac Pharma
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Non-melanoma Skin Cancer Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive non-melanoma skin cancer market growth during the next five years
• Precise estimation of the non-melanoma skin cancer market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the non-melanoma skin cancer industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of non-melanoma skin cancer market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch